“Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease.”
Gemma Salvadó, et al. – Lund University, Washington University School of Medicine.
In this study, researchers found that patients accumulate a set of 5 CSF biomarkers in a stereotypical order. Using these, they devised a staging system for amyloid and tau accumulation that agreed well with PET imaging data. This could allow for accurately staging AD pathology without the costs and expertise needed for PET imaging. Additionally, the fixed progression of biomarker buildup suggests that the mechanisms behind AD target these markers in a specific order.
This work builds directly on a previous study from this group that identified MTBR-tau243 as a CSF biomarker of tau aggregates.
